Dme Capital Management, LP Nuvation Bio Inc. Transaction History
Dme Capital Management, LP
- $2.4 Trillion
- Q3 2024
A detailed history of Dme Capital Management, LP transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Dme Capital Management, LP holds 34,995 shares of NUVB stock, worth $93,436. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,995
Previous 34,995
-0.0%
Holding current value
$93,436
Previous $102 Million
21.57%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding NUVB
# of Institutions
158Shares Held
157MCall Options Held
3.2KPut Options Held
98.7K-
Decheng Capital LLC Menlo Park, CA26MShares$69.3 Million14.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA19.2MShares$51.3 Million1.92% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$43.4 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$34.9 Million44.61% of portfolio
-
Octagon Capital Advisors LP New York, NY12.2MShares$32.5 Million6.76% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $580M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...